Clinical trials: Clear Cell RCC
Renal Cell Carcinoma, Kidney Cancer
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
- Trial name
- NCT00606632
- Testing
- 124-Iodine-cG250 (124I-cG250), CT
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Heidelberg Pharma AG
Renal Cell Carcinoma
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Primary Objective: To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b.
- Trial name
- NCT00561912
- Testing
- Decitabine, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.
- Trial name
- NCT01034631
- Testing
- Everolimus, BNC105P
- Where
- 108 sites in United States, Australia and 1 more
- Volunteers
- 154 people
- Sponsor
- Hoosier Cancer Research Network
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
SLM + Axitinib for Clear Cell RCC
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it…
- Trial name
- NCT02535533
- Testing
- Selenomethionine (SLM), Axitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mohammed Milhem
Clear Cell Renal Cell Carcinoma
Diagnostic Imaging for Clear Cell Renal Cell Carcinoma
The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
- Trial name
- RCCSCAN (NCT03185182)
- Testing
- Ioflupane I123
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Region Skane
Clear-Cell Renal Carcinoma
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Background: -Clear-cell renal cell carcinoma (ccRCC) is a kind of kidney cancer. The drug avelumab may help direct the immune response to the tumors and can prolong the immune response.
- Trial name
- NCT04150562
- Testing
- rhIL-15, Avelumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
This phase II trial is studying how well AZD2171 works in treating patients with refractory metastatic kidney cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00303862
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Cancer
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT00796757
- Testing
- bevacizumab [Avastin], interferon alfa-2a
- Where
- 50 sites in Czechia, Estonia and 10 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with kidney cancer that has spread to other parts of the body and have no evidence of disease after surgery.
- Trial name
- NCT01575548
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride
- Where
- 579 sites in United States
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non-clear Cell Renal Cell Carcinoma
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
- Trial name
- ASPEN (NCT01108445)
- Testing
- Everolimus, Sunitinib
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 131 people
- Sponsor
- Duke University
Renal Cell Carcinoma
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
- Trial name
- NCT01354431
- Testing
- nivolumab
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Bristol-Myers Squibb
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib…
- Trial name
- CANTATA (NCT03428217)
- Testing
- CB-839, Cabozantinib
- Where
- 133 sites in United States, Australia and 6 more
- Volunteers
- 444 people
- Sponsor
- Calithera Biosciences, Inc
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating patients…
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01157091
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, immunologic technique
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT04022343
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
Primary Objective: To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal cell cancer (RCC). Clinical activity will take into account response rate and progression free survival (PFS).
- Trial name
- NCT00491075
- Testing
- Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Non-Clear Cell Kidney Cancer
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
This research study is studying the combination of Atezolizumab and Bevacizumab as a possible treatment for Advanced Non-Clear Cell Kidney Cancer.
- Trial name
- NCT02724878
- Testing
- Bevacizumab, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery.
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- ASSURE (NCT00326898)
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 987 sites in United States, Canada and 1 more
- Volunteers
- 1,943 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01835158
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate
- Where
- 488 sites in United States
- Volunteers
- 157 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
This randomized phase III trial studies giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01198158
- Testing
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis
- Where
- 524 sites in United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)